Literature DB >> 10065736

Immunoglobulin variable regions usage by B-lymphocytes infiltrating a human breast medullary carcinoma.

B Kotlan1, N Gruel, B Zafrani, G Füredi, J Foldi, G G Petranyi, W H Fridman, J L Teillaud.   

Abstract

Breast medullary carcinoma are heavily infiltrated by B-lymphocytes and associated with a good prognosis despite their high histological grade. We investigated the Ig repertoire of B-lymphocytes infiltrating one such tumour. A single cell suspension was obtained from a tumor specimen by enzymatic digestion. VH, Vkappa, and Vlambda regions were amplified by RT-PCR using mixtures of primers optimized to maximize the diversity of the PCR products. They were then cloned and sequenced. Analysis of 9 VH, 5 Vkappa, and 10 Vlambda sequences using the Kabat database indicated that several VH and VL region subgroups (I, II and III) are expressed by B-lymphocytes infiltrating this tumor. The analysis of CDR3 regions also showed a variability, although some VH and VL clones exhibited identical or nearly identical sequences. Thus, the B-cell infiltration observed in this breast medullary carcinoma does not reflect a monoclonal proliferation and represents an oligoclonal or a polyclonal B-cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10065736     DOI: 10.1016/s0165-2478(98)00098-4

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  7 in total

1.  Tumor-infiltrating B cell immunoglobulin variable region gene usage in invasive ductal breast carcinoma.

Authors:  Peter Simsa; Jean-Luc Teillaud; David I Stott; József Tóth; Beatrix Kotlan
Journal:  Pathol Oncol Res       Date:  2005-07-01       Impact factor: 3.201

2.  Demonstration of light chain restricted clonal B-lymphoid infiltrates in archival bone marrow trephines by quantitative real-time polymerase chain reaction.

Authors:  U Lehmann; O Bock; F Länger; H Kreipe
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

3.  The novel panel assay to define tumor-associated antigen-binding antibodies in patients with metastatic melanomas may have diagnostic value.

Authors:  Beatrix Kotlan; Gabriella Liszkay; Miri Blank; Orsolya Csuka; Timea Balatoni; Laszlo Toth; Klara Eles; Szabolcs Horvath; Gyorgy Naszados; Judit Olasz; Balazs Banky; Jozsef Toth; Maria Godeny; Francesco M Marincola; Miklos Kasler; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

4.  Autoantibodies in breast cancer sera are not epiphenomena and may participate in carcinogenesis.

Authors:  Félix Fernández Madrid; Marie-Claire Maroun; Ofelia A Olivero; Michael Long; Azadeh Stark; Lawrence I Grossman; Walter Binder; Jingsheng Dong; Matthew Burke; S David Nathanson; Richard Zarbo; Dhananjay Chitale; Rocío Zeballos-Chávez; Carol Peebles
Journal:  BMC Cancer       Date:  2015-05-15       Impact factor: 4.430

5.  Challenging tumour immunological techniques that help to track cancer stem cells in malignant melanomas and other solid tumours.

Authors:  Beatrix Kotlan; Vanda Plotar; Klara Eles; Szabolcs Horvath; Timea Balatoni; Orsolya Csuka; Mihaly Újhelyi; Ákos Sávolt; Andras Szollar; Istvan Vamosi-Nagy; Laszlo Toth; Emil Farkas; Jozsef Toth; Miklos Kasler; Gabriella Liszkay
Journal:  Contemp Oncol (Pozn)       Date:  2018-03-05

6.  Tumor-Associated Disialylated Glycosphingolipid Antigen-Revealing Antibodies Found in Melanoma Patients' Immunoglobulin Repertoire Suggest a Two-Direction Regulation Mechanism Between Immune B Cells and the Tumor.

Authors:  Beatrix Kotlan; Szabolcs Horvath; Klara Eles; Vanda K Plotar; Gyorgy Naszados; Katalin Czirbesz; Miri Blank; Emil Farkas; Laszlo Toth; Jozsef Tovari; Andras Szekacs; Yehuda Shoenfeld; Maria Godeny; Miklos Kasler; Gabriella Liszkay
Journal:  Front Immunol       Date:  2019-04-05       Impact factor: 7.561

Review 7.  The Multifaceted Roles of B Cells in Solid Tumors: Emerging Treatment Opportunities.

Authors:  Nicole J Flynn; Rajasekharan Somasundaram; Kimberly M Arnold; Jennifer Sims-Mourtada
Journal:  Target Oncol       Date:  2017-04       Impact factor: 4.864

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.